LINATAB MOD 5/500 SR (Linagliptin 5 mg + Metformin Hydrochloride 500 mg SR Tablets)

Description

DESCRIPTION:
Linatab MOD 5/500 SR is a fixed-dose combination of Linagliptin 5 mg and Metformin 500 mg (Sustained Release), belonging to the class of oral antidiabetic medications used in the management of Type 2 Diabetes Mellitus. It is indicated for adult patients whose blood sugar levels are not adequately controlled by diet, exercise, and metformin monotherapy.

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and insufficient insulin secretion, leading to elevated blood glucose levels. Proper glycaemic control helps prevent long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular diseases.

Linatab MOD 5/500 SR combines two complementary agents that work synergistically:

• Linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which enhance insulin secretion and suppress glucagon release after meals, helping maintain glucose control.
• Metformin SR, a biguanide, reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity in peripheral tissues. Its sustained-release formulation ensures a gradual and prolonged therapeutic effect with improved gastrointestinal tolerance.

Together, these components effectively reduce both fasting and postprandial blood glucose levels, providing stable and long-term glycaemic control.

USES:

• Management of Type 2 Diabetes Mellitus in adults
• As an adjunct to diet and exercise to improve blood glucose control
• May be used as dual therapy when monotherapy with metformin or linagliptin alone is insufficient

MEDICINAL BENEFITS:

• Provides a dual mechanism of action for effective glycaemic control
• Low risk of hypoglycaemia when used as directed
• Improves insulin sensitivity and enhances endogenous insulin release
• Sustained-release formulation offers better gastrointestinal tolerance and once-daily convenience
• May support weight stability or modest reduction

DOSAGE & ADMINISTRATION:
Dosage should be individualized based on patient response and tolerance. The usual recommended dose is one tablet once daily, taken with meals to minimize gastrointestinal discomfort. Swallow the tablet whole with water. Do not crush or chew. Continue therapy as advised by the physician.

STORAGE:
Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of reach of children.

CONTRAINDICATIONS:

• Known hypersensitivity to Linagliptin, Metformin, or any component of the formulation
• Severe renal impairment or end-stage renal disease (eGFR < 30 mL/min/1.73 m²)
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis
• Conditions associated with hypoxia (e.g., heart failure, respiratory failure, myocardial infarction)

WARNINGS & PRECAUTIONS:

• Use with caution in patients with renal or hepatic impairment
• Avoid excessive alcohol consumption to reduce the risk of lactic acidosis
• Temporarily discontinue before major surgery or radiologic procedures involving iodinated contrast
• Monitor renal function and blood glucose regularly during therapy
• Use during pregnancy or lactation only under medical supervision

SIDE EFFECTS:
Common side effects may include mild gastrointestinal discomfort such as nausea, diarrhoea, or abdominal pain, especially during initial therapy. Rarely, hypoglycaemia, headache, or upper respiratory tract infection may occur. Most effects are mild and resolve with continued use.

DISCLAIMER:
Linatab MOD 5/500 SR should be used strictly under medical supervision. Dosage and duration should be based on individual clinical assessment and blood glucose monitoring.